(Photo by Christopher Wink)
When Sisu Global Health announced its most recent investment, it came from a new fund from Camden Partners. The downtown investment firm founded by David Warnock has a new fund focused on early-stage startups.
Warnock, George Petrocheilos, David Oros and Jacob Vogelstein founded the Camden Partners Exelixis Fund. Helping startups from the region’s research institutions such as Johns Hopkins, University of Maryland Baltimore, UMBC and Fort Meade is a key focus of the fund.
“We know we’ll have a direct impact on Baltimore and Maryland and the ecosystem,” Petrocheilos said.
Along with the $500,000 investment in Sisu, the fund also recently invested $250,000 in Ashvattha Therapeutics, which lists an office at the address of Johns Hopkins FastForward East, and $400,000 in Orpheris, a spinout of that company.
— Technical.ly B'more (@TechnicallyBMR) September 7, 2016
The fund, which is expected to close at the end of the year, is set to focus on areas where the partners (and plenty of others) see the region’s strengths. These areas include biomedical and digital tech companies in fields like cybersecurity, medical devices, surgical robotics, machine learning and artificial intelligence, Petrocheilos said.
The thread that runs through each is a desire for intellectual property, and a connection to the area’s universities.
Maryland as a whole gets lots of research funding, but hasn’t focused as much on turning those creations into companies. Part of that is due to a shortage of resources. The entrepreneurship pushes at Baltimore institutions are signs of growing interest in creating a systematic approach to commercializing university research, but leaders acknowledge there is still work to do.
One near-constant lament is a need for more early stage funding, which is one place where the Exelixis Fund is looking to step in.
“It was clear that there was a need for permanent source of seed-stage capital in the region,” Vogelstein said.
Oros, a longtime entrepreneur who founded Aether Systems, and Vogelstein saw that need in the fund Gamma3. Now they are looking to do it with an institutional partner with Camden Partners, which can provide additional resources.
The fund’s board of directors includes Nobel Prize–winning astrophysicist Adam Reiss, former director of DARPA’s Biological Technologies Office, Geoffrey Ling, Sourcefire and Riverbed Technologies cofounder Wayne Jackson and others. These experts can help to advise the startups, as well as the fund, Petrocheilos said.-30-
Early Charm Ventures launches Abri Science with $225K in funding
Intelehealth launches crowdfunding campaign to expand primary care access around the world
UMB grants licensing option for anticancer drug that uses Anthrax
Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program
Meet the Aerium: An algae air purifier created by IMET PhD candidates
These Howard County cybersecurity companies formed a biz partnership
5 questions with Jason Becker: Leading product development through an equity lens at Allovue
What Asymmetrik is doing to help lead healthcare’s digital transformation
Sign-up for daily news updates from Technical.ly Baltimore